Beta

Maia biotechnology, inc.MAIA.US Overview

US StockHealthcare
(No presentation for MAIA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

MAIA AI Insights

MAIA Overall Performance

MAIA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

MAIA Recent Performance

0.81%

Maia biotechnology, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

MAIA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check MAIA's Trend

MAIA Key Information

MAIA Valuation Metrics

MAIA Profile

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Price of MAIA

MAIA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

MAIA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
32.18
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.58
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
32.18
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is MAIA's latest earnings report released?

    The most recent financial report for Maia biotechnology, inc. (MAIA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating MAIA's short-term business performance and financial health. For the latest updates on MAIA's earnings releases, visit this page regularly.

  • How much cash does MAIA have?

    At the end of the period, Maia biotechnology, inc. (MAIA) held Total Cash and Cash Equivalents of 8.66M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is MAIA's EPS continuing to grow?

    According to the past four quarterly reports, Maia biotechnology, inc. (MAIA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of MAIA?

    Maia biotechnology, inc. (MAIA)'s Free Cash Flow (FCF) for the period is -7.02M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 79.64% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of MAIA?

    The latest valuation data shows Maia biotechnology, inc. (MAIA) has a Price-To-Earnings (PE) ratio of -4.04 and a Price/Earnings-To-Growth (PEG) ratio of 0.05. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.